Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fycompa in ALS
NCT03020797Terminated
- Sponsor
- Stony Brook University
- Start
- Jan 2017
- Primary completion
- Jan 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Perampanel with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at 9 months. Started Jan 2017; status: terminated.
02
Drugs
perampanel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03020797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020797.